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Background and motivation: The high-throughput genomics communities have been successfully using
standardized spreadsheet-based formats to capture and share data within labs and among public repositories. The
nanomedicine community has yet to adopt similar standards to share the diverse and multi-dimensional types of
data (including metadata) pertaining to the description and characterization of nanomaterials. Owing to the lack of
standardization in representing and sharing nanomaterial data, most of the data currently shared via publications
and data resources are incomplete, poorly-integrated, and not suitable for meaningful interpretation and re-use of
the data. Specifically, in its current state, data cannot be effectively utilized for the development of predictive
models that will inform the rational design of nanomaterials.
Results: We have developed a specification called ISA-TAB-Nano, which comprises four spreadsheet-based file
formats for representing and integrating various types of nanomaterial data. Three file formats (Investigation, Study,
and Assay files) have been adapted from the established ISA-TAB specification; while the Material file format was
developed de novo to more readily describe the complexity of nanomaterials and associated small molecules. In
this paper, we have discussed the main features of each file format and how to use them for sharing nanomaterial
descriptions and assay metadata.
Conclusion: The ISA-TAB-Nano file formats provide a general and flexible framework to record and integrate
nanomaterial descriptions, assay data (metadata and endpoint measurements) and protocol information. Like
ISA-TAB, ISA-TAB-Nano supports the use of ontology terms to promote standardized descriptions and to facilitate
search and integration of the data. The ISA-TAB-Nano specification has been submitted as an ASTM work item to
obtain community feedback and to provide a nanotechnology data-sharing standard for public development and
adoption.Introduction
As we enter the National Nanotechnology Initiative’s sec-
ond decade [1], the early concerns regarding rapid product
development without extensive regulatory review have
shifted to today’s modest commercialization rate and pur-
suit of plausible risk assessments. Responsible development
of nanotechnology will be influenced strongly by the pub-
lic’s perception of both promise and risk coupled with the
expectation that there are responsible parties addressing* Correspondence: nathan.baker@pnnl.gov
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reproduction in any medium, provided the orany remaining uncertainty [2,3]. Meeting this expectation
requires effective multidisciplinary communication that
often involves the exchange of complex datasets. The re-
sponsible development of nanotechnology products will be
empirically-driven, grounded on effective informatics [4]
for a variety of purposes; e.g., discussing ecotoxicity data
with a regulator or modeling environmental fate for the
purpose of setting appropriate disposal instructions or
regulating the design of nanoparticles for an effective bio-
logical application.
A cross-cutting need in the nanotechnology commu-
nity is the development of standards to support both
meaningful data submission to public repositories andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to move toward the rational design of nanomaterials for
biomedical and other applications, it is critical to
recognize and exploit the nanomaterial physicochemical
properties that drive biological behavior. Data mining
and computer simulation are essential for deriving this
information; however, the datasets needed to support
such modeling and computational studies are sparse and
stored across a variety of nanotechnology repositories
and resources. The lack of standardized data formats
and the non-uniformity of information reported have
proven to be significant barriers to effective and meaningful
data sharing and re-use. We have addressed this problem
by developing a spreadsheet-based data exchange format
specification, called ISA-TAB-Nano, which provides a gen-
eral framework for representing and integrating diverse
types of data related to the description and characterization
of nanomaterials. As noted by Dr. Francis Collins, open ac-
cess to technologies, tools, and databases has become in-
creasingly critical for accelerating biological discovery [6,7].
Open access databases necessitate open standards for
representing the information to be exchanged. A number
of nanomaterials resources are now becoming available
leading to an opportune moment to introduce an open
standard for nanomedicine. In this paper, we discuss the
main features of ISA-TAB-Nano file formats and how they
can be used to represent and share nanomaterial data.
Data exchange formats and their uses
The ability to share data meaningfully among investigators
from separate biomedical disciplines is a challenge [8-11].
In order to understand and use experimental data gener-
ated by another investigator, one must have sufficiently
detailed information about how the data were generated,
using mutually understood terminology. These require-
ments can be facilitated through a shared data exchange
format that captures information between two laboratories
or between investigators and public repositories. Many
XML-based and spreadsheet-based data exchange formats
have been successfully developed and adopted across the
biomedical community; examples include the SBML –
Systems Biology Markup Language [12]; BioPAX – Bio-
logical Pathway Exchange [13]; MAGE-ML – Microarray
and Gene Expression Markup Language [14]; MAGE-TAB –
Microarray Gene Expression Tabular [15]; and ISA-TAB –
Investigation/Study/Assay Tabular [16-18].
Compared to XML-based formats, spreadsheet-based
formats offer the advantage that they can be created,
viewed, and edited by the investigator using software (e.g.,
Excel) that is broadly available and familiar to most
researchers. The most widely adopted spreadsheet-based
formats of biological data are MAGE-TAB [15] and ISA-
TAB [16-18]. MAGE-TAB supports the capture and ex-
change of microarray data in accordance with the minimalinformation standards adopted in this field [19]. It was
developed in response to the need for a format that could
be created and used by laboratories lacking the dedicated
bioinformatics personnel necessary to support its prede-
cessor XML-based MAGE-ML format. The ease of use of
MAGE-TAB has facilitated its broad adoption across the
microarray community and it is supported by several
public repositories (ArrayExpress [20], caArray [21], the
Stanford Microarray Database [22]) and analysis tools
(e.g., GenePattern [23], Bioconductor [24]). In addition,
data from The Cancer Genome Atlas Project (TCGA)
are made available in MAGE-TAB format. Based on the
wide acceptance of MAGE-TAB, a generalization of this
format (ISA-TAB) was developed to support the broader
community need for a common format to support
the exchange of data about ‘omics studies employing
a combination of methodologies (e.g., genomics, tran-
scriptomics, proteomics). Multiple public and private re-
positories are now ISA-TAB compliant [25] and an
open-source tool suite has been developed to support
the use of this format [16-18].
The need for a data exchange format to share
nanomaterial data
Information describing the chemical composition and
three-dimensional (3D) structure of nanomaterials is often
represented in an unstructured fashion, with no standar-
dized way to associate this information with the assay data
from characterization studies. Nanomaterials are diverse:
chemical composition, size, geometry, morphology and
surface chemistry all play important roles in determining
the biological properties of resulting nanomaterials. Com-
plex nanomaterials are often multi-component systems
formulated with small molecules for specific biomedical
applications such as drug delivery, imaging, and detection
of diseases. Such complex formulations make the repre-
sentation of exact chemical composition, physical struc-
ture, and properties very challenging and very necessary.
Nanomaterial analysis requires knowledge of the
characterization experiment details so that the results can
be accurately and interpreted. Nanomaterial interactions
with biological systems are complex and, accordingly,
associated data are often generated at multiple levels of
detail. The properties of nanomaterials are analyzed based
on the data available from different characterization stud-
ies, such as in vitro and in vivo analysis of biological activ-
ities and abiotic studies of physicochemical properties.
Each characterization itself involves a wide range of vari-
ables using different types of assays, which can also vary
depending on the endpoint measured, technology used,
and the protocol applied. Furthermore, even minor varia-
tions in the chemical composition, assay protocols and
conditions, and time point of analysis (the elapsed time
since the nanomaterial was synthesized), can give rise to
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measurements on nanomaterial properties depend on
non-standardized protocols and diverse instrumentation
technology types. Experimental results are dependent on
protocol details that are not consistently captured or
reported [26]. For example, measurements of certain para-
meters, such as size, are dependent on the instrumenta-
tion and the sample preparation method; this information
needs to be captured in the form of metadata to fully in-
terpret such measurements.
ISA-TAB-Nano specification
To address the challenges associated with the sharing
and re-use of nanomaterial data, we have developed the
ISA-TAB-Nano specification, a standard format for
representing and sharing data pertaining to the descrip-
tion and characterization of nanomaterials. ISA-TAB-
Nano is intended to facilitate the submission and ex-
change of assay metadata and nanomaterial descriptions,
along with other information (raw/derived data, image
data, protocol information), among individual research-
ers and to/from nanotechnology online resources. We
expect that ISA-TAB-Nano will provide organizations
with a standard approach to representing nanomaterial
data that will enable researchers to share nanomaterial
information effectively and to make cross-material
comparisons.
Methods
In 2008, the Nanotechnology Working Group (Nano
WG) was established as part of National Cancer Insti-
tute (NCI) cancer Biomedical Informatics Grid (caBIGW)
program, to support the informatics needs of nanomedi-
cine researchers. Today, the group has over 20 active
participants who represent a broad range of expertise
and come from academic, industrial, government agency
and other institutions. Beginning in March 2010, a sub-
group of the Nano WG began developing a specification
to facilitate the exchange of nanomaterial data amongst
research labs and with public repositories of nanoparti-
cle information. An important goal of this effort from
the outset was to use and extend concepts from the
caBIGW Life Sciences Domain Analysis Model [27] while
using the NanoParticle Ontology [28] and other ontolo-
gies as terminology sources. Recognizing that nanoparti-
cle assays have many of the same challenges as
microarray assays, the Nano WG looked to the micro-
array community for lessons learned. The ISA-TAB
standard [16,18] forms the basis for our ISA-TAB-Nano
format because of its flexibility in supporting several dif-
ferent types of assays of interest including physicochem-
ical, in vitro, and in vivo assays.
The ISA-TAB-Nano file formats were evaluated using sev-
eral nanomaterial datasets from the cancer NanotechnologyLaboratory Portal (caNanoLab) [29] and individual
researchers with applications ranging from biomedicine
to nanotoxicology. This diversity allowed for format re-
finement and enabled support for a broad range of
interests. Test case studies were conducted and feed-
back was provided to the ISA-TAB-Nano development
team. Example datasets are available from the ISA-
TAB-Nano website at https://wiki.nci.nih.gov/x/HgiG.
Basis of ISA-TAB-Nano
ISA-TAB
The ISA-TAB-Nano specification is based on the ISA-
TAB specification [16-18,25]. ISA-TAB defines three file
formats for sharing the metadata associated with ‘omics
(e.g., proteomics, genomics, metabolomics, and tran-
scriptomics) – based experiments. The three files are
called Investigation file, Study file, and Assay file. Non-
standard (user-defined) file formats such as image files,
spreadsheet files containing raw/derived data, and proto-
col documents, can also be referenced in appropriate
fields within the Investigation, Study, and Assay files. By
providing a standard format for representing the meta-
data related to each ‘omics experiment, the ISA-TAB file
formats facilitate the integration and sharing of ‘omics
data in a meaningful and standardized way.
The ISA-TAB Study file is used to record information
about the source and characteristics of a subject (sam-
ple) under study as well as the different treatment proto-
cols that are applied to prepare the samples for the
analysis (assay). The subject under study could be an or-
ganism, a sample taken out of the organism, or any
other sample. The Assay files are used to record the
assay metadata along with references to the names (or
URIs) of the raw/derived data and image files. In the
ISA-TAB framework, the type of assay is determined by
the endpoint of measurement and by the technology
(technique) used to measure that endpoint. Therefore, a
single study (of a given sample) can comprise several
types of assays. The Investigation file serves to relate the
different types of assays to their corresponding studies.
In particular, the Investigation file is used to record
reference information about each Study file and Assay
file; point of contact; publications; the parameters,
instruments, software, and reagents of a protocol; the
factors of the study (a factor is defined as any independ-
ent variable that is varied in an experiment to investigate
its effect on the subject under study) and the termin-
ology sources referred to in the Investigation, Study and
Assay files.
Biospecimens versus material samples
An important extension to ISA-TAB required to support
nanomaterials came from the need to distinguish sam-
ples derived from biological sources (e.g., from cell lines,
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biological sources (e.g., nanoparticle formulations, small
molecule drug, etc.). Hence, for the ISA-TAB-Nano spe-
cification, we consider a sample derived from biological
sources as a biological specimen or biospecimen material
type, while referencing samples derived from non-
biological sources as material samples.
The ISA-TAB Study file can be used to describe the
source and characteristics of biological specimens, how-
ever, it is not suitable for describing nanomaterials. In
this work, we have designed a “Material” file format for
describing nanomaterials. In general, this file format is
applicable for describing any material sample, nanoscale
or otherwise, as discussed later. Hence, in ISA-TAB-
Nano, the concept of a sample (as used in ISA-TAB spe-
cification) is extended to distinguish between biological
specimens and material samples by incorporating infor-
mation about the latter into the Material file.
Scope of a ISA-TAB-Nano Material file
The Material file is designed to capture information
related to the description of nanomaterials. Typically,
the description of a nanomaterial is complex and
includes different types of information (name, type, char-
acteristics) related to the whole nanomaterial and its in-
dividual chemical components. A typical example is that
of a nanoparticle formulation [5,28], which can be gener-
ally described as a multi-component system containing
chemical components that may be distinguished as
nanoparticles, chemical constituents of the nanoparticle,
functionalizing agents, and components of the medium
in which the nanoparticles may be suspended. These
chemical components can be described and identified
based on their molecular structure, biochemical role,
and function [28]. The types of information needed to
describe nanoparticles and their formulations include
specification of the linkages existing between the differ-
ent components of the formulation (e.g., encapsulation,
entrapment, amide linkages, etc.); the physical state of
the formulation (e.g., emulsion, solid, hydrogel, etc.); the
properties (physical, chemical, and functional) of each
chemical component; the intended functions and appli-
cations of the nanoparticle; the nanoparticle design prin-
ciples (or rationale); and the type of stimulus that may
be required for activating a specific function of the
nanoparticle (e.g., magnetic field, ultrasound, pH change,
etc.) [28]. All of these types of information were taken
into account when developing the specification for the
ISA-TAB-Nano Material file format.
Results and discussion
The ISA-TAB-Nano specification makes use of the ISA-
TAB Investigation, Study, and Assay files to record and
share the assay metadata. In addition to sharing theassay metadata, we also want to share the endpoint mea-
surements and description (chemical composition, charac-
teristics) of both nanomaterials and small molecules (e.g.,
drugs, imaging agents). To accommodate this additional
information, we have made extensions to ISA-TAB. In
particular, the ISA-TAB Study file is suited for recording
the source and characteristics of biological specimens and
for specifying any treatments performed on them. How-
ever, the Study file is not designed to represent informa-
tion about the chemical composition and characteristics
of material samples (nanomaterials, drugs, imaging
agents, and other small molecules). To represent this in-
formation, we have introduced a fourth ISA-TAB-Nano
file called the Material file. We use the Material file to de-
scribe material samples while using the ISA-TAB Study
file to describe biospecimens. We have modified the defini-
tions of some of the field names in the ISA-TAB Investiga-
tion, Study, and Assay files and added new fields names to
expand the scope of information that needs to be shared
using the ISA-TAB-Nano specification. Detailed informa-
tion of the field names and definitions of each file format
can be found in Supporting Information. For more
detailed information about the structure and contents of
the ISA-TAB files, the reader may refer to the ISA-TAB
specification [25]. The rules for naming the four file for-
mats defined in the ISA-TAB-Nano specification are
i_xxxx.txt for the Investigation file, s_xxxx.txt for the
Study file, a_xxxx.txt for the Assay file, and m_xxxx.txt for
the Material file, where ‘xxxx’ denotes a unique string.
The following sections describe the different compo-
nents of the ISA-TAB-Nano files. Supporting Informa-
tion provides additional materials to supplement the
manuscript discussion, including a summary of exten-
sions to the ISA-TAB format, the standard specification,
and examples.
Types of information shared using ISA-TAB-Nano files
The types of information shared using ISA-TAB-Nano
pertain to the material samples, biospecimens, assays,
and protocols. As listed in Table 1, we use the ISA-TAB-
Nano Material file to capture information about material
samples and references to the external material data files
(e.g., image files, structural data files); the Investigation
file to enter reference information about each investiga-
tion, study, assay, protocol: the Study file to capture in-
formation about biospecimen source and characteristics,
names and attributes of protocols used in the prepar-
ation of samples analyzed in an assay; and, the Assay file
to capture information about measured values of end-
point variables and references to external files (raw/
derived data files, image files) related to each analyzed
biospecimen or material sample. In the following sec-
tions, we explain how to record and share the different
types of information in each ISA-TAB-Nano file.
Table 1 Types of information entered in the four ISA-TAB-Nano files
No. ISA-TAB-Nano file Types of information entered in each ISA-TAB-Nano file
1. Investigation file Reference information about each investigation, study, assay, protocol, Study file, and Assay file.
2. Study file Names and attributes of protocols used for preparing samples for analysis; source and characteristics
of biospecimens.
3. Assay file Values of measured endpoint variables and references to external data files for each analyzed sample.
4. Material file Descriptions of the material sample and its structural parts and chemical components; linkage
descriptions between chemical components; reference information about external material data files.
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In the ISA-TAB-Nano framework, all material samples are
viewed as formulations having one or more chemical
components (e.g., nanoparticles, small molecules, solvent
medium, etc.). The ISA-TAB-Nano material file has been
designed for recording descriptions of various types of for-
mulations, ranging from a simple chemical compound to
a complex multi-component nanoparticle formulation.
The layout of the ISA-TAB-Nano Material file is same
as that of the Study and Assay files, wherein the field
names are arranged as columns and material sample in-
formation is entered as rows. Columns in the ISA-TAB-
Nano Material file provide information on the material
and its components, the relationship between materials
and components, and any associated data files, as men-
tioned in Table 1.
Using the ISA-TAB-Nano Material file to describe a
material sample and its components
The Material file is used to describe a material sample
and its structural and chemical components. There are
different ways to identify the components, depending on
how the sample is viewed at its various levels of molecu-
lar and structural granularities. Figure 1 shows a process
flowchart that can be used as a basis for identifying dif-
ferent components of the material sample. Once a com-
ponent is identified, its description can be entered as a
row in the Material file.
In Figure 2, we show an example of the ISA-TAB-
Nano Material file that contains information about a
hypothetical dendrimer sample (LAB-1) and its compo-
nents. The first row (row 2) of the Material file is used
to identify the material sample name (identifier, chemical
name), type, synthesis type, design rationale, intended
application, and nominal characteristics. Subsequent
rows of the Material file are used to identify the different
structural parts and chemical components of the sample
including their name, type, nominal characteristics, and
intended application. While row 2 represents the dendri-
mer sample LAB-1, rows 3, 4, and 5 represent the com-
ponents (core molecule, branch, and terminal group) of
the dendrimer sample. From the given information, one
can understand that the dendrimer sample (LAB-1) is a
4.5 generation dendrimer that has a molecular weight of27 kilodaltons (kDa). Ontology terms can be identified
by the name of the source ontology (defined by Term
Source REF labels) and their identification numbers
(defined by Term Accession Number labels) used within
the ontology. Thus, we use row 2 to describe the mater-
ial sample as a whole, and subsequent rows to describe
each material sample component. If a material sample
that is described in a Material file is also a component of
another material sample, then the components of the
former sample need not be specified in the Material file
of the latter sample. To illustrate this scenario, we con-
sider another hypothetical sample called LAB-2 that
contains both LAB-1 and an image contrast agent called
MagnevistW (LAB-3). Figure 3 shows the LAB-2 Material
file, where row 2 represents the whole LAB-2 material
sample and rows 3 and 4 represent its components
(LAB-1 and LAB-3). Note that we did not have to enter
information about each component of LAB-1 since
that information is already present in the LAB-1 Mater-
ial file (see Figure 2). The LAB-2 Material file describes
the material sample LAB-2 which consists of nanoparti-
cles composed of carboxyl-terminated PAMAM dendri-
mer complexed with MagnevistW, a small molecule
gadolinium-based image contrast agent. The dendrimer
is conjugated to the MagnevistW and is intended to be
used as a delivery vehicle for image contrast agents like
MagnevistW in MRI applications.
Using the ISA-TAB-Nano Material file to describe linkages
in a material sample
The ISA-TAB-Nano Material file is used to describe the
whole material sample and its components with respect
to their name, type, characteristics, synthesis, design ra-
tionale, and intended application. In addition, the Mater-
ial file can be used to identify the chemical components
and represent how they are linked or connected to each
other with respect to a nanoparticle. Any two chemical
components in a typical multi-component nanoparticle
formulation can be linked to each other by one of the
three types of linkages: encapsulation, entrapment, or
covalent linkage [28]. We can describe linkages between
the different chemical components of a nanoparticle
sample as shown in Figure 4. In the figure, one can iden-
tify that there is a covalent linkage that exists between
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material sample
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Figure 1 Flowchart depicting the ways to identify different components of a material sample, and to guide the creation of rows for
each component in the ISA-TAB-Nano Material file. (A) The overall ISA-TAB-Nano file creation process which includes (B) the creation of
molecular component entries.
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The term “covalent linkage” is used here as a generic
term. Normally, if the specific type of covalent linkage is
known (e.g., amide linkage, disulfide linkage, etc.), then
one should use the appropriate term identifying that
linkage. The NPO [28] provides several terms (theirnames and definitions) for describing different types of
linkages that can be typically found in a nanoparticle
sample. Additionally, we have recently developed a sim-
ple nomenclature system for describing the specific
chemical linkages in nanoparticle formulations [30]. It is
important to ensure that the names of the two chemical
Figure 2 Example of an ISA-TAB-Nano Material file with information about a dendrimer nanoparticle sample, identified as LAB-1.
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(Figure 4) match their respective names given in the
Material Name field.
Using the ISA-TAB-Nano Material file to record
information about external files that provide additional
information about the material sample
The Material file is also used to record the name or URI
of external files that contain additional information
about the material sample. Examples include image files
displaying the chemical structures of molecules, or
documents (e.g., spreadsheet, Word, PDF, etc.) that con-
tain detailed descriptions of the sample. The example
given in Figure 4 references one file called “magnevist.
jpg” that contains an image of the molecular structure of
MagnevistW.
In practice, one ISA-TAB-Nano Material file should be
created for each material sample in a study. When using
the format “m_xxxx.txt” to name the Material files, the
string “xxxx” should exactly match the string used in the
Material Source Name field of the sample’s Material file.
For example, we would name the Material file of samplesLAB-1 and LAB-2 as m_LAB-1.txt and m_LAB-2.txt,
respectively.
Sharing assay information
Different types of assays are performed to measure the
physicochemical, in vitro, and in vivo properties of ma-
terial samples. We can identify the type of each assay
based on the measured endpoint, measurand, and tech-
nique used. For example, if an assay is related to a size
characterization study, the endpoint could be “size” and
the technique could be “dynamic light scattering (DLS)”,
or “scanning electron microscopy (SEM)”, or other rele-
vant technique. The corresponding assay types are “size
by DLS assay”, “size by SEM”, etc. Assays of the same
type may be performed using different protocols, by dif-
ferent people, at different dates, and under different ex-
perimental conditions. To interpret the characterization
results of a material sample meaningfully, we need to
have information about the assay type; biospecimen in-
formation (if it is a bioassay); protocol descriptions;
dates of synthesis and analysis of the material sample;
the measured endpoint variables; as well as the protocol
Figure 3 Example of an ISA-TAB-Nano Material file with information about a dendrimer-magnevist nanoparticle complex sample,
identified as LAB-2.
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cification, variables that are kept constant in an assay ex-
periment are termed “parameters”, while variables that
are changed for studying their effects on the measured
endpoint values are termed “study factors”.Figure 4 An example showing the representation of linkages among
Material file.Representing physiochemical characterization data of
material samples using ISA-TAB-Nano files
In a physicochemical characterization study, one mea-
sures the properties of a material sample and studies
how these properties are affected by the study factors.components of a nanoparticle sample in the ISA-TAB-Nano
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ial sample and may even suspend each sample in differ-
ent test media to achieve solution conditions suitable for
performing a specific assay. Therefore, each analyzed
sample may have its own identifier while its (source)
material sample to be characterized has a different iden-
tifier (the Material Source Name).
Figure 5 and Figure 6 show an example of how to use
the Study and Assay files, respectively, to represent the
assay data (metadata, summary data) of each sample
analyzed in a size characterization assay using DLS tech-
nique. In this example, the goal of the study was to de-
termine the effect of varying temperature and solvent
medium on the size of nanoparticles in the two material
samples - LAB-1 and LAB-2.
Study file
In the ISA-TAB Study file, a column Source Name is
used to define the source of a biospecimen. ISA-TAB-
Nano extends the ISA-TAB Study file by adding a col-
umn called Material Source Name REF to refer the
source name of the material sample, given in the Mater-
ial Source Name column of the sample’s Material file.
Thus, as shown in Figure 5, the first column of the
Study file (Material Source Name REF) represents the
identifier of the material sample that is to be character-
ized. The second column contains the name of theFigure 5 An example showing the layout of the ISA-TAB-Nano Studyprotocol applied to prepare each individual biospecimen
or material sample for the analysis. After the protocol
column, we create columns to capture the attributes of
the protocol including the name of the person who per-
formed the protocol, the date when the protocol was ap-
plied, and the values of each parameter in the protocol.
After these, we add two more columns to record the
sample name (identifier) and its material type.
Assay file
The first column of the Assay file is used to enter the
biospecimen or material sample names under the header
name Sample Name (see Figure 6) – note that these
names should match the names entered in the Sample
Name column of the Study file. The names of the assay
and protocol are entered in the next two columns. As in
the Study file, we also create columns to capture the
attributes of each protocol, including investigator, date,
and parameter values. We also create columns for enter-
ing the values of each factor value and measurement
value variables, followed by columns to record the URIs
or names of associated data files, as shown in Figure 6.
The values for the parameters, factors, and measure-
ments can be qualified by a unit of measurement and a
statistical type (if applicable) using column headers Unit
and Statistic, respectively, in both the Study as well as in
the Assay files (see Figure 5 and Figure 6). Note that thefile.
Figure 6 An example showing the layout of the ISA-TAB-Nano Assay file.
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tic columns are newly added by the ISA-TAB-Nano spe-
cification. If terms from an ontology are used as valid
values in any of the columns of the Study and Assay
files, it is necessary to enter the term’s identifier and
source ontology name in adjacent columns named as
Term Accession Number and Term Source REF, respect-
ively (not shown in the Figure 5 and Figure 6). One may
choose to enter the factor values either in the Study file
and/or in the Assay file, as appropriate to the actual ex-
perimental procedure(s). Furthermore, to enter any add-
itional type of information in the Study or Assay file,
one may create a column with header name, Comment
[<string>], as specified by ISA-TAB.
Investigation file
The Investigation file is a reference for the different
assays and protocols that have been conducted in a sin-
gle study. The Investigation file is divided into several
sections (listed in Table 2), including Study, Study
Assays, Study Factors, and Study Protocols. As summar-
ized in Table 2, the Study section is used to record infor-
mation about each study and its Study file (see
Figure 7A). The Study Assays section is used to recordinformation about each assay and its assay file, particu-
larly, the assay and technology types, measurement vari-
able names, and the assay file names (see example in
Figure 7B). The Study Factors section is used to record
the names of factor variables and the factor type, as
shown in Figure 7C. The Study Protocols section is used
to record information about each protocol, including the
name, type, description, URI file references and version
of each protocol; as well as names of parameter variables
and components (instruments, reagents, and software)
of each protocol (an example is given in Figure 8). It
should be noted the above information must be recorded
in the Investigation file for reference to them in the indi-
vidual Assay and Study files.
Note that the ontologies or controlled vocabularies
referenced in any of the ISA-TAB-Nano files must be
declared in the Ontology Reference section of the Inves-
tigation file (noted in Table 2). The Investigation file can
also contain information about publications and point of
contact associated with an investigation or a specific
study within the investigation (also noted in Table 2).
For more details on the Investigation file, we refer the
reader to the ISA-TAB specification [25] and ASTM
ISA-TAB-Nano specification [31].
Table 2 Types of information entered in the eleven sections of the ISA-TAB-Nano Investigation file
No. Sections of Investigation file Types of information entered in each section
1. Ontology Source Reference Information about the ontologies referenced in the ISA-TAB-Nano files.
2. Investigation Investigation title and description.
3. Investigation Contacts Point(s) of contact for the whole investigation.
4. Investigation Publications References to publications of an investigation.
5. Study Information about each study and its associated Study file.
6. Study Design Descriptors Type of study design.
7. Study Contacts Point(s) of contact for a study.
8. Study Publications References to publications of a study.
9. Study Assays Information about each assay and its associated Assay file.
10. Study Factors Names of factor variables and types.
11. Study Protocols Information about each protocol.
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characterization data of material samples using
ISA-TAB-Nano files
For in vitro and in vivo characterization studies, one is
interested in measuring the effects of a material sample on
a biological system, such as a cell line or animal model. In
these studies, the material sample plays the role of a factor,
and the sample analyzed is a biospecimen. The way we
enter the in vitro/in vivo characterization data is similar to
how we entered the physicochemical characterization dataFigure 7 Examples showing how information is represented in the fo
Assays, and (C) Study Factors.in the Investigation, Study, and Assay files. The only add-
itional information to be entered is the description of the
source and characteristics of the biospecimen in the Study
file, as illustrated in Figure 9. Note that we use the column
Characteristic [<name>] to enter the type of the biological
source, as specified by ISA-TAB. The material type of the
sample is entered as biospecimen in the Material Type
column, and the material representing the nanoparticle or
other non-biological material is entered in the Factor
Value column. Particularly, the non-biological materialllowing sections of the Investigation file: (A) Study, (B) Study
Figure 8 An example showing how information is represented in the Study Protocols section of the Investigation file.
Figure 9 A representative Study file for a hypothetical in vitro cytotoxicity characterization study, showing the description of a
biological specimen and attributes of the sample preparation protocols. Note that the entered information is not from an actual study and
is only used for illustration purposes.
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that entered in the Material Source Name column of the
sample’s Material file.
Integrated view of ISA-TAB-Nano files and external
referenced documents
ISA-TAB-Nano files support the aggregation of all infor-
mation pertaining to the description and characterization
of material samples. In Figure 10, we show how the ISA-
TAB-Nano files and the external files, such as protocol
documents, raw data files, derived data files, image files,
and material sample description files, can be assembled
within the ISA-TAB-Nano framework. The names of all
Study and Assay files are recorded in the Investigation file
in columns corresponding to the fields Study File Name
(Study section) and Study Assay File Name (Study Assays
section), respectively. As a result, the Investigation, Study
and Assay files are linked. The data in the Study and Assay
files for each sample are integrated through the Sample
Name fields found in both of the files. This is illustrated in
Figure 5 and Figure 6, where the sample names in Column
A of the assay file (a_LABsizeDLS.xls) are the same as
those found in Column P of the study file (s_LABsizeDLS.
xls). Thus, the information of each biospecimen or mater-
ial sample in the Study and Assay files can be linked to
each other. If the sample that is analyzed is a material
sample, then it is necessary to ensure that the value ofFigure 10 Links (black arrows) between ISA-TAB-Nano files and refere
derived data files, image files, and material description files).Material Source Name REF entered in the Study file
matches the string entered in the Material Source Name
of its Material file (Figure 10). Similarly, the same string
must be used in the Factor Value column of the study file
or assay file for material samples that are used as factors
in an in vitro or an in vivo study. As shown in Figure 10,
the ISA-TAB-Nano files can also be associated with any
external files, as long as the URI or the names of these
files are referenced in the appropriate fields in the ISA-
TAB-Nano files. Specifically, the ISA-TAB-Nano files are
associated with protocol documents by referencing the
URIs or names of these documents in the Study Protocol
URI field of the Investigation file. The external files related
to the description of a material sample are associated via
the Material Data File field of the material file. Finally,
the Assay file associates the raw data, derived data and
image files via the column fields, Raw Data File, Derived
Data File, and Image File, respectively.
Validation of ISA-TAB-Nano files
A key feature of ISA-TAB-Nano (and the parent ISA-
TAB format) is that it can be readily created and edited
with any spreadsheet software, without the need for spe-
cialized bioinformatics support. However, this also cre-
ates challenges because such software does not enforce
validation rules for ISA-TAB-Nano files. One possible
solution to this problem is to adapt the suite of opennces (blue arrows) to documents (protocol documents, raw/
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[16-18], such as: (1) ISACreator, which provides a graph-
ical user interface for entering in data into ISA-TAB
files; (2) ISAValidator, which assesses the validity of ISA-
TAB files; (3) ISAConverter, which converts an ISA-TAB
file to one of several other formats if so desired, (4) ISA-
Configurator, which creates the XML files that define
specialized versions of ISA-TAB, and (5) bioinvindex,
which is a database for storing ISA-TAB files. These
tools are part of our future plans to be tested for editing
and validating ISA-TAB-Nano files.
XML-based validation is also of interest and would in-
volve developing an ISA-TAB-Nano XML schema based
on the ISA-TAB-Nano specification such that any ISA-
TAB-Nano XML file converted from the ISA-TAB-Nano
files can be formally validated against the XML schema.
Having an XML-based validation service would also en-
able software systems to import and export validated
ISA-TAB-Nano files to and from distributed nanotech-
nology resources.
Conclusions
In this paper, we have provided an overview of ISA-TAB-
Nano, a spreadsheet-based exchange format for informa-
tion pertaining to the description and characterization of
nanomaterials. The ISA-TAB-Nano specification extends
the ISA-TAB specification that was designed for sharing all
types of ‘omics data. Specifically, ISA-TAB-Nano leverages
the three primary ISA-TAB file formats - Investigation file,
the Study file, and the Assay file - to represent the meta-
data related to the characterization of nanomaterials. To
capture the measurement data, ISA-TAB-Nano specifies
new fields in the Investigation file and in the Assay file. In
addition, ISA-TAB-Nano includes a new file format, the
Material file, to capture the description of nanomaterials
and chemical substances (drugs, imaging agents, etc.)
that are characterized in an assay. The ISA-TAB-Nano
specification was recently submitted as an ASTM work
item to obtain community feedback and to promote ISA-
TAB-Nano as a voluntary consensus standard for the
nanotechnology community. Additionally, we hope that
the ISA-TAB-Nano standard will be adopted by journals
and other organizations to ensure a uniform representation
of information that is too often “lost” in a prose Methods
section and cannot be easily extracted for re-use.
Many of the ISA-TAB extensions developed for ISA-
TAB-Nano could also be used for studies of other types
of complex materials or formulations. In particular, the
“Material” file addition is likely to be useful outside of the
nanotechnology realm for a broader range of samples with
complex composition or structural characteristics.
Key to promoting the successful adoption of ISA-TAB-
Nano will be the availability of resources to facilitate the
creation and validation of these files. Our adherence tothe parent ISA-TAB specification will allow the ready
adaptation of the ISA Tools [16-18] to support the
extended framework, an anticipated next step for this pro-
ject. The ability easily select ontology terms when populat-
ing the files is critical to the ultimate goal of integrating
these data across disparate resources. The ISA-TAB and
ISA-TAB-Nano specifications support the use of any
ontology or controlled vocabulary; in this domain, pre-
ferred ontologies include NanoParticle Ontology (NPO)
[28], Chemical Entities of Biological Interest (ChEBI) [32],
Gene Ontology (GO) [33], NCI thesaurus (NCIt) [34], and
Unit Ontology (UO) [35]. The Nano WG continues to ex-
pand the NanoParticle Ontology (NPO) to support the
needs of ISA-TAB-Nano, and is considering various meth-
ods and tools for facilitating the use of ontology terms in
ISA-TAB-Nano files. (Additional files 1, 2 and 3).
Additional files
Additional file 1: This Supporting Information provides a summary
of ISA-TAB-Nano extensions to the ISA-TAB format, glossaries for
the terms used in the ISA-TAB-Nano specification, and an overview
of the worked examples and templates provided in the other
supporting files.
Additional file 2: This file contains the examples described in
Supporting File 1.
Additional file 3: This file contains ISA-TAB-Nano templates for
common assays.
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